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Introduction: Radiotherapy with or without systemic therapy is the main treatment for locally 
advanced head neck cancer (HNC) patients. This treatment can cause mucositis, dysphagia and 
severe (neuropathic) pain. Adjunctive analgesics could play a significant role in the treatment of 
neuropathic pain in cancer patients. Our aim was to give an overview of the effectiveness of 
adjunctive analgesics in HNC patients receiving (chemo)-radiotherapy. 
Methods: This systematic review was conducted following the PRISMA guidelines. PubMed, 
Embase, Web of Science, The Cochrane Library and Clinicaltrials.gov were searched for studies 
concerning “head neck cancer”, “adjunctive analgesics”, “pain” and “radiotherapy”.  
Results: Nine studies were included in our synthesis. Most studies were of low quality and had a 
high risk of bias on several domains of the Cochrane Collaboration tool. Only two studies 
comprised high quality randomised controlled trials in which pregabalin and a doxepin rinse 
respectively showed their effectiveness in HNC patients receiving (chemo-)radiotherapy. 
Conclusion: More high quality trials (randomised controlled trials, using standardised pain 
scales) are necessary to provide clear evidence on the effectiveness of adjunctive analgesics, 






Head and neck cancer (HNC) incidence is rising. In Belgium, there were 2694 new diagnoses in 
2016 [1]. It is speculated that by 2020, there will be 151.000 new diagnoses in Europe and 
833.000 worldwide [2]. Treatment modalities for HNC include surgery, radiotherapy, 
chemotherapy, biotherapy, immunotherapy, targeted therapy and brachytherapy. In most cases, 
or combinations of these are used [3–5]. Systemic therapy combined with radiation is the main 
treatment for locally advanced HNC patients [6]. However, this treatment may cause severe pain 
and other complications.  
Cancer pain can be classified as followingin three categories: tumour induced pain, iatrogenic 
pain (induced by the therapiestreatment) and incidental pain (caused by co-existing conditions) 
[3]. In HNC patients, pain is often a serious complication and is present in a high proportion of 
patients [3,6–8], before (50%), during (81%) and after treatment (70%) [6]. This may be acute 
pain caused by inflammation of the mucosa (mucositis) and of the skin (dermatitis), or late pain 
caused by radiation-induced fibrosis [6]. Post-operative pain is another possibility [3]. 
Neuropathic pain is also often reported [9,10]. Neuropathic pain is defined by the International 
Association for the Study of Pain (IASP) as pain initiated or caused by a primary lesion or 
dysfunction in the nervous systems, resulting in debilitating pain [11]. This can be caused by 
tumour infiltration or by therapy [9,10]. In case of neuropathic pain due to tumour infiltration, 
nociceptive and neuropathic components are involved, therefore referred to as mixed pain. In 
case of neuropathic pain by cancer therapy, it can be considered as pure neuropathic pain, 
therefore referred to as purely neuropathic pain [10]. Pain may have a substantial impact on the 
patients’ quality of life (QOL) [6] and could lead to social isolation, functional impairment and 
emotional and spiritual distress [8]. Moreover, it could lead to reduced treatment compliance, 
dose modifications or treatment interruption and in that way, causing a lower patient survival 
[6,8]. Therefore, optimal pain control is essential. 
The World Health Organisation (WHO) developed pain guidelines, including the WHO pain 
ladder consisting of three steps that should be followed in case of pain: first oral administration 
of non-opioids, then mild opioids and afterwards finally strong opioids (e.g. morphine) until pain 
relief is obtained [3]. These WHO guidelines for pain relief were have been validated for both 
cancer pain in general asnd for HNC pain specifically. In these guidelines, the WHO advises to 
use adjuvant pain medications too for pain treatment in HNC, as these treatments are highly 
effective and relatively safe [3]. For mixed pain, adjuvant analgesics could be used next to 
opioids. For purely neuropathic pain, the WHO suggests the use of adjuvant analgesics as first 
line treatment [10].  
In the past, opioids (e.g. morphine) were considered as standard treatment for cancer pain 
management and radiation-induced pain in HNC patients [6,12]. However, its use is impeded 
because of thbye multiple side effects such as nausea, vomiting, depression, sedation, 
drowsiness, hallucinations, cognitive impairment, pruritus, constipation, and respiratory 
depression [6,7,12]. Opioids are narcotic medications drugs and have addictive properties [13]. 
Moreover, certain types of pain, such as neuropathic pain, respond poorly to opioids alone 
[6,12]. As aBy consequence, escalating doses are required [11,12]. Adjuvant analgesics could be 
a possible alternative.  
Adjuvant analgesics can be defined as drugs with a primary indication other than pain, but with 
analgesic properties under certain circumstances [8,14]. TheyIt can also be defined as drugs that 
do not contain acetaminophen and those not classified as non-steroidal anti-inflammatory or 
opioid agents, but play a role in the management of chronic pain [15]. Another term is adjunctive 
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analgesics, which may be better fit, as these drugs are often already used as first-line therapy 
[8,15]. Therefore, in this systematic review, we will use the term adjunctive analgesics. 
Adjunctive analgesics could play an important role in the treatment of neuropathic pain in 
cancer patients [16]. There are different classes of adjunctive analgesics comprising including 
anticonvulsants, tricyclic antidepressants (TCA), selective serotonin and norepinephrine 
reuptake inhibitors (SSNRI), NMDA receptor antagonists, topical agents and others 
(cannabinoids, clonidine, corticosteroids, etc.) [8,9,14]. Anticonvulsants include gabapentin and 
pregabalin and are suggested to help relieve neuropathic cancer pain [8,9,14]. Other 
anticonvulsants investigated are lamotrigine, oxcarbazepine, topiramate, levetiracetam [14]. 
TCAs include amitriptyline, imipramine, clomipramine, doxepin, nortriptyline and desipramine 
and have been prescribed for years to treat neuropathic pain [9,14]. SSNRI, also antidepressants, 
have shown efficacious analgesic effects in the treatment of neuropathic pain and include 
venlafaxine and duloxetine [8,9,14]. Concerning NMDA receptor antagonists, ketamine may be a 
possible treatment for chronic cancer pain [8,9,14]. Cannabinoids also have analgesic properties 
and could be used for the management of neuropathic cancer pain [8,9,14]. Alpha-2 (α-2) 
adrenergic agonists, such as clonidine and tizanidine have been used for neuropathic cancer 
pain, but their specific role has not been established [9,14]. Further, corticosteroids, such as 
dexamethasone and methylprednisolone, could be effective for cancer pain relief [8]. Last, local 
anaesthetics, such as lidocaine and mexiletine can decrease pain intensity [8,14].  
Oral mucositis is one of the most commonly reported adverse events in HNC patients receiving 
(chemo-)radiotherapy, which causes pain that can range from mild to severe and can persist up 
to 6 months after the completion of radiotherapy, or more [5]. Therefore, benzydamine or other 
mouthwashes can be used as treatment for this mucositis which could result into pain relief as 
well [17].  
In this systematic review, we give an overview of the effectiveness of adjunctive analgesics in 
HNC patients receiving (chemo-)radiotherapy. 
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This systematic review was conducted following the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement for reporting systematic reviews [18]. The 
protocol was registered in the International Prospective Register of Systematic Reviews-
PROSPERO (CRD42018085632). 
Eligibility criteria 
We aimed to identify all types of studies (cohort studies, randomised controlled trials, etc.) that 
included head neck cancer patients receiving curative (chemo-or bio-) radiotherapy and that 
investigated the effectiveness of adjunctive analgesics. All articles reporting pain or pain 
management as outcome were included. Only articles in English were included. Papers reporting 
on pain prevention were excluded.  
Literature search method 
The following databases were searched: PubMed, Embase, Web of Science and The Cochrane 
Library. Clinicaltrials.gov was consulted for ongoing clinical trials. Studies published up until 
February 2019 were included. The search terms that were used are listed in table 1.  
 
Table 1: Search terms 
Head and neck 
cancer 
Head neck cancer; Head neck tumor; Head neck tumour; Head neck 
neoplasm; Head neck malign; Head neck carcinoma 
Pain Pain; Pain medication; Pain management ; Pain measurement; Pain 
assessment; Analgesia 
Radiotherapy Radiotherapy; Radiation 
Adjunctive 
medication 
Adjunctive medication/analgesia; Adjuvant medication/analgesia; Co-
analgesic; Off-label; Off label; Anticonvulsant; Antiepileptic; 
Gabapentin; Pregabalin; Topiramate; Lamotrigin*: Carbamazepine; 
Levetiracetam; Oxcarbazepine; Tiagabine; Zonisamide; Phenytoin; 
Valproate; Antidepressant; Anti-depressant; Tricyclic antidepressant; 
TCA; Amitriptyline; Nortriptyline 
Desipramine; Selective serotonin reuptake inhibitor; SSRI; Serotonin 
inhibitor; Noradrenaline inhibitor; SNRI; Paroxetine; Citalopram; 
Venlafaxine; Duloxetine; Imipramine; Doxepin*; Bupropion; 
Clomipramine; Fluoxetine; Mirtazapin; Sertraline; N methylaspartate 
antagonist*; N-methylaspartate inhibitor; Ketamine; Memantine; 
Dextromethorphan; Methadone; Amantadine; Antipsychotic; 
Neuroleptic; Antipsychotic agents; Chlorpromazine; Clozapine; 
Olanzapine; Haloperidol; Pimozide; Quetiapine; Risperidon*; 
Sulpiride; Tiaprid*; Zuclopenthixol; Zoledronic*; Pamidronate*; 
Clodronate; APD; Lidocaine*; Capsaicin*; BTX-A; Botulinum toxin; 
Corticosteroid*; Dexamethasone; Prednisone; Denosumab; 
Bisphosphonate; Biphosphonate; Cannabinoid; Local anaesthetic; 
Local anesthetic; Clonidine; Tizanidine; *Adrenergic agonists; 
Mexiletine; Mouth wash 
 
The search in PubMed was narrowed by filtering studies concerning humans. At the Cochrane 
Library, the search was limited to title, abstract and keywords. At clinicaltrials.gov, the condition 
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described was “head and neck cancer”, the intervention “pain medication” and “radiotherapy” 
was completed under the category “other”.  
All studies were gathered in a self-constructed database. After removal of duplicates, title and 
abstract were screened by two individual reviewers (TL and PDB). The remaining studies were 
screened for eligibility by the two reviewers independently. On the selected studies, a 
snowballing approach was applied: reference lists were screened for additional eligible studies.  
Quality assessment 
The included studies were subjected to a critical quality assessment, using The Cochrane’s 
Collaboration Tool, by two individual reviewers (TL and LT). In this way, studies were judged 
based on selection, performance, detection, attrition and reporting or other forms of bias [19].  
Data extraction 
The following data was extracted from the articles: study characteristics (first author, country, 
article type, drug, comparison, sample size, primary site of disease and chemotherapy received), 
study therapy characteristics (dose, indication, comparison, number of patients) and outcome 
(pain outcome, adverse events and toxicity and other reported outcomes e.g. mucositis, quality 
of life, depression, etc.).  
Due to the high heterogeneity in the reported data from the studies, performing a meta-analysies 







We obtained 264 records from our database search and after removal of duplicates, 216 articles 
were left. After screening on title and abstract, we maintained 74 articles. The main reasons for 
exclusion was becausewere that the articles did not concern adjunctive analgesics orand did not 
concern HNC patients. After full-text screening and quality analysis, nine articles were included 
for analysis in this review. No additional studies were identified through snowballing (Figure 1).  
 
Figure 1: PRISMA flowchart of the search 
 
Risk of Bias assessment 
The six domains of the Cochrane Collaboration tool for risk of bias were assessed for each of the 
included studies (Figure 2). On the first domain (random sequence generation), four of the nine 
studies had a low risk of bias and five had a high risk of bias. For the next domain, allocation 
concealment, three studies had a low risk of bias, five had a high risk of bias and for one study, 
the risk of bias was unclear. There was a high risk of bias for the domain “blinding of 
participants and personnel” in six studies, a low risk in two studies and an unclear risk in one 
study. On the domain “blinding of outcome assessment”, two studies had a low risk of bias, five 
had a high risk of bias and two an unclear risk of bias. In the next domain (incomplete outcome 
data), a low risk of bias was judged in eight studies and an unclear risk of bias in one study. On 
the last domain (selective reporting), eight studies were judged to have a low risk of bias and 
one to have a high risk of bias. Six studies had a high risk of bias due to a low sample size and the 
8 
 
lack of a power calculation. This bias was categorised under “other bias”. Three studies did 
include a power calculation and had an acceptable sample size, resulting into a low risk of bias. A 
summary of the bias assessment is presented in figure 2. The extensive judgement can be found 











































































































































































Jiang et. al. 
2018 [20]        
Bar Ad et. al. 
2010 [13]        
Bar Ad et al. 
2010 [12]        
Kataoka et. al. 
2016 [11]        
Starmer et. al. 
2014 [21]        
Leenstra et. al. 
2014 [22]        
Ehrnrooth et. 
al. 2001 [23]        
Hartl et. al. 
2007 [24]        
Oguchi et. al. 
1998 [25]        
Figure 2: Bias risk of included articles 
 
Study and study therapy characteristics 
A summary of the study and study therapy characteristics can be found in Appendix A and B 
respectively. Four studies were performed in the United Stated of America (USA) [12,13,21,22], 
one in China [20], one in Denmark [23], one in France [24] and two in Japan [11,25]. Four 
studies were randomized trials [11,20,22,23], two were retrospective cohort studies [12,13], 
one was a prospective cohort study [24] and two were historically controlled studies [21,25].  
Four studies investigated the effect of gabapentin [11–13,21], one of pregabalin [20], one of a 
doxepin rinse [22], one of nortriptyline [23], one of botulinum toxin [24] and one investigated a 
polymer film containing tetracaine [25]. Study medication was indicated for neuropathic pain in 
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one study [20], for painful mucositis in six studies [11–13,22,23,25], for pain in general in one 
study [21] and for radiation induced pain, trismus and masticator spasm in one study [24].  
 
Pain outcomes 
Different methods were used to measure the effectiveness of the adjunctive analgesic on pain. 
Most studies utilised patient reported measures, such as the numeric rating scale (NRS) [20], the 
Brief Pain Inventory-Short Form (BPI-SF) [20], a visual analogue scale (VAS) [11,23], an 11-
point numerical analogue pain scale [22], the Pain Likert Scale [23], the McGill Pain 
Questionnaire (Danish version) [23], or patient reported pain (not specified) [21,24,25]. 
However, some studies also looked at the use of pain medications e.g. the use of adjunctive pain 
medication [12,13], or additional pain medication such as acetaminophen [11], opioids [11–
13,23], or other analgesics [21–23,25]. Because of this variety, we could not perform a meta-
analysis to obtain an overall result of all studies included. An overview of the reported pain 
outcomes can be found in Appendix C and are described below. 
Pregabalin 
Jiang et. al. [20] conducted a randomized, double-blind, placebo-controlled trial including 64 
patients in each group (pregabalin and placebo) and found a decreased pain intensity of 2.44 on 
the NRS at week 16 in the pregabalin group compared to the placebo group (p=0.003). 19 out of 
64 patients receiving pregabalin achieved pain relief of 50% or more at week 16 compared to 
only five out of 64 patients receiving placebo (p=0.003). Moreover, pain intensity decreased 
gradually from week 1, but more in the pregabalin group than in the placebo group (p<0.001). 
Also, at week 16, a significantly decreased pain severity, measured by the BPI-SF, was observed 
in the pregabalin group compared to the placebo group (p=0.047). 
Gabapentin 
Four studies explored the effectiveness of gabapentin in HNC patients receiving radiotherapy 
[11–13,21] of which two were retrospective cohort studies [12,13], one was a historically 
controlled study [21] and one a randomised trial [11].  
Bar Ad et. al. [13] performed a retrospective cohort study in 29 patients and observed that 28 
patients used the median dose of gabapentin of 2700 mg/day at week 3, 4, 5 and 6 and that at 
week 3 and 4, only three of the 29 patients required low doses of narcotics (15-30 mg/day 
Roxicodone). At week 5 and 6, ten patients required additional low doses of narcotics (15-40 
mg/day Roxicodone). 
In a consequent retrospective cohort study in 42 patients, Bar Ad et. al. [12] observed that at 
week 2, 3, 4 and the last week of radiotherapy, 38 patients used gabapentin. Only five patients 
required an additional median dose of 10 mg/day oxycodone-equivalent at week 2. At week 3, 4, 
and the last week of radiotherapy, 14 patients required 10 mg/day oxycodone equivalent, 23 
patients required 30 mg/day oxycodone equivalent and 30 patients required 60 mg/day 
oxycodone-equivalent respectively.  
Kataoka et. al. [11] compared gabapentin plus standard pain control (SPC) to SPC alone in a 
randomised trial in 20 patients (9 in gabapentin group; 11 in SPC group). They established a 
significant difference in maximum VAS score in the gabapentin group compared to the SPC 
group (74 vs. 47 resp., p=0.552). However, no difference in VAS score was detected between 
groups at each time point from baseline till week 4. No significant difference was found in the 
number of days until use of additional analgesics acetaminophen and opioids between groups. 
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Starmer et. al. [21] compared gabapentin to standard treatment (including use of narcotic pain 
medications) of historical controls in a cohort of 46 patients. They observed significantly lower 
maximal pain scores in the gabapentin group compared to the control group (p=0.038). 
Moreover, in the gabapentin group, 13% of the patients did not require additional pain 
medication compared to the control group, in which all patients required narcotics and 70% 
required multiple narcotics analgesics.  
Doxepin rinse 
Leenstra et. al. [22] compared a doxepin oral rinse to a placebo rinse in a randomised double 
blind trial including 140 patients. The area under the curve (AUC) for mean mouth and throat 
pain reduction was greater in the doxepin group (-9.1) compared to the placebo group (-4.7) 
(p<0.001). The treatment difference after cross-over analysis was -3.5 (p<0.001). After 30 
minutes, the average mouth and throat pain score reduction was -2.0 in the doxepin group 
compared to -1.0 in the placebo group (p=0.0032). A significant difference in pain reduction was 
observed 1, 2, 3 and 4 hours after study initiation. No significant difference in use of additional 
analgesics was found after 2 and 4 hours between groups (8.8% vs. 2.9% and 16.9% vs. 14.5% 
respectively).  
Nortriptyline 
Ehrnrooth et. al. [23] analysed nortriptyline versus oral morphine in a randomised trial (19 
patients in the nortriptyline group, 20 in the morphine group) and found significant lower VAS 
scores in the opioid group compared to the nortriptyline group one and two weeks after 
randomisation (p=0.007 and p=0.04 respectively). However, no significant changes in pain were 
observed between groups from baseline to one and two weeks post-randomisation. There was a 
trend to higher pain scores on the Pain Likert scale in the nortriptyline group compared to the 
opioid group at baseline and one week post-randomisation (not significant). According to the 
McGill Pain Questionnaire, there we no significant differences between groups in sensory, 
affective or miscellaneous pain at the four time points.  
Botulinum toxin 
Hartl et. al. [24] performed a prospective cohort study to observe the effect of botulinum toxin 
on pain in 19 patients. They found pain being reported on average 5.6 years after radiotherapy 
and a significant pain improvement after one month of botulinum toxin therapy (p=0.002). 
However, painful muscle cramps recurred in 11 patients 3.5 months after injection. 
Polymer film containing tetracaine 
Oguchi et. al. [25] used a historically controlled design to compare the effect of a polymer film 
containing tetracaine (AD film; 25 patients) and topical anaesthetics (27 patients). A 
significantly higher complete pain relief was obtained at rest and while eating in the AD film 
group compared to the control group (82% vs. 44% and 68% vs. 22% respectively). No 
significant difference was observed between both groups in duration of complete pain relief (30’ 
vs. 30’-2h). Partial and complete pain relief was comparable in both groups. In the AD film 
group, median duration of grade 3-4 oral pain was 10 days compared to 15 days in the control 
group. Only four patients in the AD film group needed systemic analgesics due to grade 3-4 oral 
pain compared to 21 patients in the control group. 
Reported adverse events and toxicity 
An overview of the reported adverse events and toxicities isare described below and isare 




In the study of Jiang et. al. [20], 35 patients (54.7%) in the pregabalin group and 29 patients 
(45.3%) in the placebo group experienced at least one adverse event (p=0.29). Adverse events 
described were dizziness, somnolence, facial oedema and increased pain. 
Gabapentin 
A small number of patients experienced mild side effects or gabapentin related toxicities: four 
patients (13%) in the study of Bar Ad et. al. [13], two patients (5%) in the other study of Bar Ad 
et. al. [12], three of the 9 patients (33%) in the study of Kataoka et. al. [11] and three of the 23 
patients (13%) in the study of Starmer et. al. [21]. The toxicities described comprised dizziness, 
nausea, vomiting, follicular skin rash/ allergic skin reaction, somnolence, vertigo, headaches and 
fatigue. 
Doxepin rinse 
In the study of Leenstra et. al. [22], stinging and burning, bad taste and drowsiness were 
reported following toxicities concerninguse of the doxepin rinse were reported: stinging and 
burning, bad taste and drowsiness. 
Nortriptyline 
Ehrnrooth et. al. [23] reported minor side effects in 14 patients in both the nortriptyline (74%) 
and control group (70%): nausea, vomiting, constipation, cardial arrhythmia and neurocortical 
symptoms. 
Botulinum toxin 
Hartl et. al. [24] only reported the painful injections of the botulinum toxin as toxicity (37%). 
Polymer film containing tetracaine 
Oguchi et. al. [25] did not have any toxicities or side effects to report. There were no acute or 
chronic adverse effects on the oral mucosa or gastrointestinal tracts, no allergic dermal 
reactions, no cases of haematological toxicity and no cases of aspiration pneumonia or 
bronchitis. 
Other reported outcomes 
The focus of this systematic review was the effect of adjunctive analgesics on pain in HNC 
patients receiving (chemo-)radiotherapy. However, adjunctive analgesic could have other 
beneficial effects that should be taken into account, such as improvements in psychological 
distress, in quality of life (QoL), lower depression, better functionality and less cramps, 
improvements in radiation induced mucositis, better nutritional management and less weight 
loss, less secondary infections and a better tumour control and better survival. These are 
described below and are summarised in Appendix E. 
Pregabalin 
Jiang et. al. [20] investigated psychological distress and observed a significant improvement in 
all subscales of the Profile of Mood States-Short Form (POMS-SF), but not on the Vigor-Activity 
and Confusion-Bewilderment subscales in the pregabalin group compared to the control group.  
Looking at the QoL, significant improvements could be observed in the physiology and 
psychology domains of the WHO Quality of Life – BREF (WHOQOL-BREF) scores in the 
pregabalin group compared to placebo (p=0.004 and p=0.01 resp.).  




The Patients Global Impression of Change (PGIC) and the Clinical Global Impression of Change 
(CGIC) were used to follow up on the improvement and satisfaction of patients with 
treatment. The PGIC scale showed 30 patients (47.6%) that reported treatment success in the 
pregabalin group, as opposed to eight patients (12.9%) in the placebo group (p<0.001). The 
CGIC showed 36 patients (57.1%) with treatment success in the pregabalin group, compared to 
ten patients (16.1%) in the placebo group (p<0.001). 
12.5% of the patients in the pregabalin group used rescue medication, while this number was 
40.6% in the placebo group (p<0.001).  
Compliance was comparable in both groups: 80.5% of patients took 80% or more of their 
prescribed medication. 
Gabapentin 
Bar Ad et. al. followed in both studies [12,13] up on radiation induced mucositis and 
radiation induced dysphagia. In their first study [13], all patients developed mucositis. During 
the first two weeks of treatment, grade 1 and 2 mucositis occurred in 80% of the patients. By 
week 2, 3 and 4, grade 2 mucositis occurred in 13%, 53% and 73% of the patients respectively. 
By week 5 and 6, grade 2 or 3 occurred in 80% of the patients. Grade 3 mucositis occurred in 6% 
of the patients and no grade 4 mucositis was reported.  
During week one of treatment, one patient (3%) reported dysphagia. By week 4 and 6, 53% and 
60% of the patients respectively reported grade 1 dysphagia. Grade 2 dysphagia was reported 
by one patient (3%) during this trial, starting at week 3. Grade 3 dysphagia was reported by two 
patients (6%) during week 3 and by one patient (3%) by week 6. 33% of patients did not report 
any swallowing difficulty. No grade 4 dysphagia was reported. 
In their subsequent study [12], all patients developed mucositis. Grade 1 and 2 mucositis 
occurred in 88% of the patients during the first 2 weeks of treatment. Grade 2 mucositis 
occurred in 44% of the patients during week 2. Grade 3 mucositis was not reported by week 2, 
but occurred in 17%, 45%, 60% and 81% of the patients by week 3, 4, 5 and 6 respectively. 
Grade 2 mucositis or higher occurred in 71%, 86%, 95% and 100% of the patients by week 3, 4, 
5 and 6 and again, no grade 4 mucositis was reported. 
During week one of treatment, two patients (5%) reported grade 1 dysphagia. By week 2 and 3, 
grade 1 or 2 dysphagia was reported by 38% and 52% of the patients respectively. By week 4, 
76% of the patients reported dysphagia with 36% grade 2 or 3. By week 5 and 6, 95% of the 
patients reported dysphagia with 48% grade 2 or 3. No grade 4 dysphagia was reported. 
Kataoka et. al. [11] also followed up on oral mucositis and reported that all patients 
experienced oral mucositis. Grade 3 or 4 mucositis occurred in 45.5% of the patients in the 
control group compared to 63.6% in the gabapentin group. 
Concerning QoL, no significant decrease was observed in most domains over four weeks of 
radiotherapy between both groups. Weight gain was significantly higher in the gabapentin 
group compared to the control group (p=0.0062). 
Starmer et. al. [26] focussed on percutaneous endoscopic gastrostomy (PEG) use and 
physiological outcomes. PEG use was later in the gabapentin group compared to the historic 
control group (3.7 vs. 2.29 weeks; p=0.013) and the PEG tube was removed earlier removed 
(7.29 and 32.56 weeks; p=0.039). 21.7% of patients in the gabapentin group never used their 
PEG tube compared to 4.3% in the control group (p=0.038). Patients in the gabapentin group 
lost on average 7.45% weight, on average, while this was 11% in the control group (p=0.037). 
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Velopharyngeal closure, tongue base retraction, laryngeal elevation, epiglottic tilt and 
pharyngeal constriction were less affected in the gabapentin group. Significantly lower 
penetration-aspiration scale (PAS) scores were found in the gabapentin group compared to the 
control group (1.89 vs. 4.0; p=0.052), indicating better airway protection. Significantly higher 
functional oral intake scale (FOIS) scores were found in the gabapentin group compared to the 
control group (5.4 vs. 3.21; p=0.0003) indicating more advanced diet levels. 
Doxepin rinse 
No other outcomes were reported by Leenstra et. al [22]. 
Nortriptyline 
Ehrnrooth et. al. [23] used the Beck’s Depression Inventory (BDI) to assess the degree of 
depression. A significant reduction in BDI scores was observed in the nortriptyline group 
compared to the oral morphine group (p=0.02).  
Botulinum toxin 
Hartl et. al. [24] determined the functionality and cramps of the patients included and 
observed a significant improvement in overall functional score (p=0.04) and muscular cramps 
(p=0.04) after botulinum toxin injection. There was no significant improvement in jaw opening. 
Polymer film containing tetracaine 
Oguchi et. al. [25] observed mucositis in 88% of the patients in the AD film group compared to 
92% in the control group.  
17 patients in the AD film group did not require intra venous (IV) infusions or 
hyperalimentation compared to nine patients in the control group. In the AD film group, less 
weight loss and a better weight recovery was observed compared to the control group (not 
significant).  
No secondary bacterial or fungal infection of the oral cavity and/or oropharynx was observed 
in the AD film group compared to 4 cases of oral infection and 2 cases of aspiration pneumonia 
in the control group. 
No significant difference in 3-year local control rate was found between both groups (96% vs. 








In this systematic review, our aim was to provide an overview of the effectiveness of adjunctive 
analgesics in HNC patients receiving (chemo-)radiotherapy. Out of the 216 articles obtained 
through our database search, we could select and include nine studies relevant to this topic and 
meeting the inclusion criteria. Four studies concerned research into gabapentin, an 
anticonvulsant [11–13,21]. Another anticonvulsant, pregabalin, was investigated in a study by 
Jiang et. al [20]. The four remaining studies investigated the effect of a doxepin rinse [22], 
nortriptyline [23], botulinum toxin [24] and a polymer film containing tetracaine [25] 
respectively.  
Pregabalin, originally an anticonvulsant, is recommended by several guidelines for the use in 
several chronic neuropathic pain conditions, including diabetic neuropathy and postherpetic 
neuralgia. Jiang et. al. could demonstrate a significant decrease in pain intensity and severity, 
improved mood states and a higher quality of life in patients treated with pregabalin compared 
to placebo. Some patients experienced dizziness, somnolence, facial oedema and increased pain, 
but overall, pregabalin therapy was well tolerated. This was a high quality trial with a  low risk 
of bias on all domains of the Cochrane Collaboration tool, meaning these results are highly 
reliable [20]. 
Gabapentin, similar to pregabalin, has been used to treat several neuropathic pain syndromes, 
including diabetic neuropathy, postherpetic neuralgia, chronic pain, post-operative pain and 
trigeminal neuralgia. Bar Ad et. al. proposed in both included studies that gabapentin could be a 
promising treatment to avoid or reduce the need for narcotic pain medication in HNC patients 
receiving radiotherapy [12,13]. Furthermore, Starmer et. al. could demonstrated other positive 
results of gabapentin: lower less pain, shorter pain duration and less use of narcotics. PEG use 
was also later, the PEG tube was could be earlier removed earlier and less patients actually used 
their PEG tube. Swallowing function was better maintained too [21]. However, these studies had 
a high risk of bias on several domains of the Cochrane Collaboration tool, due to the low sample 
size and the design of the studies as it were two retrospective cohort studies and one historically 
controlled study. Kataoka et. al. performed a randomised trial comparing gabapentin to standard 
treatment. They could not demonstrate a beneficial effect of gabapentin [11]. Two domains of 
the Cochrane Collaboration tool comprised a high risk of bias and two domains comprised an 
unclear risk of bias. Therefore, further research is necessary to provide evidence on the 
effectiveness of gabapentin. 
Doxepin hydrochloride is a tricyclic antidepressant and when administered topically, it has 
anaesthetic and analgesic properties. This doxepin rinse was shown to be statistically 
significantly superior to a placebo rinse in the treatment of oral mucositis pain caused by HNC 
radiotherapy. Pain reduction was significantly higher [22]. This comprised a highly qualitative 
trial with a low risk of bias, therefore contributing to reliable results. 
Nortriptyline, also a tricyclic antidepressant, is proved to have analgesic properties. 
Nortriptyline was shown to provide sufficient pain control in some HNC patients, but opioids 
generally provided better pain relief. As expected, depression scores were lower in patients 
receiving nortriptyline [23]. Despite the randomised trial design of this study, an uncertain risk 
of bias was present for three domains of the Cochrane Collaboration tool. More trials are 
necessary to determine the effectiveness of nortriptyline in HNC (chemo-)radiation induced 
pain. It should be noted that in trials investigating pain outcome, the experimental medication is 
often compared to morphine, while it would be of more interest to perform a comparison 
between the experimental medication in combination with morphine versus placebo in 
combination with morphine instead.  
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Botulinum toxin has mainly been used for the treatment of muscle stiffness, spasticity and 
dystonia, but also for various types of neuropathic pain. In a study of Oguchi et. al., the injection 
of botulinum toxin significantly improved pain scores and masticator spasms in HNC patients 
with radiation induced pain. However pain recurred in 11 of 19 included patients 3.5 months 
after injection [24]. The study had a high risk of bias on five of the seven domains of the 
Cochrane Collaboration tool, suggesting more research is needed to prove its usefulness in HNC 
(chemo-) radiation pain. 
A polymer film containing tetracaine was developed to treat acute radiation-induced oral 
mucositis. It comprised tetracaine, ofloxacine, miconazole, guaiazulene and triacetin. A study of 
Oguchi et. al. proved the usefulness of this polymer film to relieve radiation-induced mucositis 
pain, to maintain a good nutritional management and to prevent secondary oral infections [25]. 
However, this study had a high risk of bias on almost all domains of the Cochrane Collaboration 
tool. Moreover, study it dates from 1998 and results could be outdated. After more than 20 
years, no more recent study was found investigating this polymer film into more detail. 
Therefore, the actual effectiveness of this polymer film in reducing HNC pain has not been 
established. 
Next to the adjunctive analgesics discussed above, there are many other adjunctive analgesics 
that have been suggested to be beneficial for cancer pain, including antidepressants e.g. 
amitriptyline, venlafaxine, duloxetine imipramine, but also NMDA receptor antagonists e.g. 
ketamine, or others like cannabinoids [8]. However, in our literature search, no evidence was 
found of the effectiveness of these agents for HNC radiation induced pain.  
As pain in HNC patients is often caused by radiation induced mucositis, in addition to pain 
caused by the tumour itself, in our search we also included mouth washes that perhaps 
wouldmay contain adjunctive analgesic agents. However, most mouthwashes are used in the 
prevention of oral mucositis and not as treatment of pain, which was beyond the scope of this 
systematic review. Therefore, no studies with e.g. magic mouthwash were included. Yet, we 
would like to emphasise the importance of prophylaxis and maintenance of oral hygiene with 
help of mouth washes such as chlorhexidine mouth washes and others [17,27,28]. Nevertheless, 
research into mouth washes e.g. granulocyte-colony-stimulating factor mouthwashes has also 
shown contrary results, so more investigations would be necessary to provide clear evidence on 
the role off these mouthwashes [29–32]. Low-level laser therapy (LLLT) is another option for 
the prevention and treatment of oral mucositis [33]. This treatment option lies beyond the scope 
of this systematic review, but is definitely worth mentioning. 
As referred to before, the WHO guidelines support the use of adjunctive analgesics for HNC pain. 
Following the three step pain ladder, acetaminophen, NSAIDs and opioids play also a significant 
role [3,5,10]. An optimal management guideline for HNC pain has not been developed yet, as for 
this, more high quality trials are necessary [3,6]. 
There are some limitations toof this systematic review. First, because of the high heterogeneity 
of parameters reported in the trials, we were not able to perform a meta-analysis to obtain a 
clear comparison between trials. The included studies used different tools to evaluate pain and 
other outcomes, making this impossible. Next, two of the included studies [20,24] investigated 
the effect of the adjunctive analgesic after radiotherapy, which is a different approach compared 
to the other studies investigating the effect during radiotherapy. Yet, in our opinion, these 
studies were of too high value to be excluded from our analysis. Last, due to the low quality of 
most of the included studies, it is hard to provide clear evidence of the reported outcomes.  
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At the moment, there is only evidence of the effectiveness of pregabalin and a doxepin rinse for 
the treatment of HNC (chemo-)radiation induced pain. We can therefor conclude that more 
research would beis necessary to provide clear evidence onf the effectiveness of other 
adjunctive analgesics. More randomised trials, using standardised pain scales, would be a great 
contribution to this research question.  Comment [TB16]: Why don’t you 
mention that you will try to address 
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Appendix A: Study characteristics 
Author Country Article type Drug Comparison Sample size Primary site of disease Chemotherapy received 




Pregabalin Placebo N = 128 
 
nasopharynx, lip and oral cavity, larynx, oropharynx, paranasal 
sinus, other 
50 (78,1%) in the pregabalin group; 47 (73,4%) in 
the placebo group 






N = 30 
 
Salivary gland tumours, thyroid cancer, skin cancer, 
oropharyngeal squamous cell carcinoma, oral cavity squamous 
cell carcinoma, unknown primary squamous cell carcinoma, 
paragangliomas, laryngeal squamous cell carcinoma 
No chemotherapy, only 2 pts cetuximab 






N = 42 Oropharyngeal squamous cell carcinoma, oral cavity squamous 
cell carcinoma; laryngeal and hypopharyngeal squamous cell 
carcinoma; paranasal sinuses carcinoma; sinonasal 
undifferentiated carcinoma; nasopharyngeal squamous cell 
carcinoma 
all pts; 21 pts platinum-based chemo every 3 
weeks (cisplatin + etoposide, cisplatin + 
cetuximab); 18 pts weekly systemic therapy 
(carboplatin + paclitaxel); 3 pts unknown chemo 
Kataoka et. 
al. 2016 [11] 








N = 22 
 
Oral cavity, nasopharynx, oropharynx, hypopharynx, 
oropharynx and hypopharynx, larynx 
 
 
all pts: cisplatin 
Starmer et. 








N = 46 tongue base of tongue, tonsil, soft palate all pts 
Leenstra et. 
al. 2014 [22] 
USA Randomised 
double blind trial 
Doxepin 
rinse 
Placebo rinse N = 155 
 
Oropharyngeal, oral cavity, laryngeal, nasopharyngeal, salivary, 
hypopharyngeal, not specified 
110 from 140 pts received chemotherapy 
Ehrnrooth et. 
al. 2001 [23] 
Denmark Randomised trial Nortriptyline Oral 
morphine 
N = 43  
 
Larynx, pharynx, oral cavity not reported 








N = 19  nasopharynx, oropharynx, oral cavity, oral cavity and 
oropharynx, larynx, parotid gland 
11 pts chemotherapy 









N = 52 
 
squamous cell carcinoma or oral cavity 7 pts in AD film group and 5 in comparison group 
(peplomycine 5 mg iv twice a week for 1-3 weeks 






Appendix B: Study therapy characteristics 
Author Drug Dose Indication Comparison Number of patients 
Jiang et. al. 
2018 [20] 
Pregabalin max 600 mg daily (p.o.) neuropathic pain Placebo N = 128 
64 in pregabalin group, 64 in placebo group 
Bar Ad et. al. 
2010 [13] 
Gabapentin median dose of 2700 mg/day (p.o.) pain control, mucositis 
 
No comparison N = 30 
29 included in analyses 
Bar Ad et al. 
2010 [12] 
Gabapentin median dose of 2700 mg/day (p.o.) mucositis, dysphagia, pain No comparison N = 42 
Kataoka et. 
al. 2016 [11] 
Gabapentin start at 300 mg from the initiation of RT, 
escalated every 3 days by 300mg/day up to 
900 mg/day (maintained till 4 weeks after 
RT) (p.o.) 
 
pain related to radiation 
induced mucositis 
Standard pain control (SPC) 
(acetominophen + opioids) 
N = 22 
20 included in analyses 
11 in SPC group, 9 in gabapentin group 
Starmer et. 
al. 2014 [21] 
Gabapentin 2700 mg/day  (p.o.) pain Standard treatment (including narcotic pain 
medication) 
N = 46 
Leenstra et. 
al. 2014 [22] 
Doxepin 
rinse 
10mg/mL+2,5mL, diluted to 5mL with 
2,5mL of sterile or distilled water (oral 
rinse) 
oral mucositis pain placebo rinse (prepared in similar manner: 
Ora-Sweet SF = alcohol-free flavoured 
sugerfree syrup vehicle = placebo base 
solution 
N = 155 
140 included in primary endpoint analyses, 129 
included in crossover analyses 
Ehrnrooth et. 
al. 2001 [23] 
Nortriptyline start with 25 mg x 2, increased by 25 mg 
every second day, until pain relief or 
intolerable side effects or until max of 150 
mg/day (pts older than 60y received 50% of 
all doses) (p.o.) 
 
painful mucositis oral morphine (morphine chloride: start 
with 5mg x6, and additional doses per 5 mg; 
titration to acquire pain relief without 
intolerable side effects; steady state pts 
converted to morphine sulphate 
N = 43  
39 included in analyses 
19 in nortriptyline group, 20 in morphine group 




50 units of Botox, 250 units of Dysport per 
muscle (transcutaneous injection) 
radiation induced pain, 
trismus and masticator 
spasm 
No comparison N = 19  





(p.o.) oral mucositis pain topical anaesthetics (viscous lidocaine, 
Xylocaine) and/or general systemic 
analgesics 
N = 52 





Appendix C: Reported pain outcome 
Author Drug Comparison Number of patients Method of pain 
assessment 
Results 
Jiang et. al. 
2018 
Pregabalin Placebo N = 128 
64 in pregabalin 








At week 16, pain intensity was decreased by 2.44 (SD, 1.52) in the pregabalin group vs. 1.58 (SD, 1.25) in the 
placebo group (p=0.003). 19/64 pts in the pregablin group vs 5/64 in the placebo group achieved pain relief of 
50% or more at week 16 (p=0.003). Pain intensity decreased gradually from week 1, more in the pregabalin 
group vs placebo group (p<0.001). 
 
Significantly decreased pain severity in pregabalin group compared to placebo (p=0.047) at week 16. 
Bar Ad et. al. 
2010 
Gabapentin No comparison N = 30 





At week 3, 4, 5 and 6, 28 pts used gabapentin median dose 2700 mg/day.  
 
At week 3 and 4, 3 pts required additional low doses of narcotics (15-30mg/day Roxicodone). At week 5 and 6, 
10 pts required additional low doses of narcotics (15-40 mg/day Roxicodone). 
Bar Ad et. al. 
2010 
Gabapentin No comparison N = 42 Gabapentin use 
 
Opioid use 
At the 2nd, 3rd, 4th and last week of RT, 38 pts used gabapentin. 
 
At the 2nd week of RT, 5 pts required additional median dose of 10 mg/day oxycodone-equivalent. At the 3rd week 
of RT, 14 pts required 10 mg/day oxycodone-equivalent, at the 4th week of RT, 23 pts required 30mg/day 
oxycodone-equivalent and at the last week of RT, 30 pts required 60 mg/day oxycodone-equivalent. 
Kataoka et. 
al. 2016 
Gabapentin Standard pain control 
(acetominophen + 
opioids) 
N = 22 
20 included in 
analyses 






n or opioid use 
Maximum VAS score in the gabapentin group was 74 vs 47 in standard of care group (p=0.552). 
From baseline to week 4, no difference in VAS score was detected between groups at each time point. 
 
13 days till starting acetaminophen in the gabapentin group vs 15 days in the standard of care group (p=0.7898). 




Gabapentin Standard treatment 
(including narcotic 
pain medication) 





Significantly lower maximal pain scores between gabapentin and control group (p=0.0003). Pain duration was 
shorter in the gabapentin group vs control group (p=0.038).  
 
In the gabapentin group, 13% required no additional pain medication. In the control group, all pts required 






(prepared in similar 
manner: Ora-Sweet SF 
= alcohol-free 
flavoured sugaer-free 
syrup vehicle = placebo 
base solution 
N = 155 
140 included in 
primary endpoint 
analyses, 129 










AUC for mean mouth and throat pain reduction was greater in the doxepin group (-9.1) compared to the placebo 
group (-4.7) (p<0.001).  
Treatment difference after cross-over analyses was -3.5 (p<0.001). 
Average mouth and throat pain score reduction of -2.0 in the doxepin group compared to -1.0 in the placebo 
group after 30 minutes (p=0.0032). Significant pain reduction after 1, 2, 3 and four hours since study initiation.  
 
No significant difference in use of additional analgesic agents after 2-hours and 4-hours (8.8% vs 2.9% and 
16.9% vs 14.5% respectively). 
Ehrnrooth et. 
al. 2001 
Nortriptyline oral morphine 
(morphine chloride: 
start with 5mg x6, and 
additional doses per 5 
mg; titration to acquire 
pain relief without 
intolerable side effects; 
steady state pts 
converted to morphine 
N = 43  
39 included in 
analyses 
19 in nortriptyline 











Significant lower VAS scores in opioid group compared to nortriptyline one and two weeks after randomisation 
(p=0.007 and p=0.04 respectively).  
No significant changes in pain between groups from baseline to one and two weeks post-randomisation.  
 
Trend to higher pain scores in nortriptyline group versus opioid group at baseline and one week post-
randomisation (not significant). 
 















11 pts in the nortriptyline group needed additional morphine versus zero in the opioid group, on average 13.4 
days (+-8.4) since the start of nortriptyline. 
 
None of the pts needed concomitant analgesics. 




No comparison N = 19  Reported pain Pain reported on average 5.6 years after radiotherapy.  
Significant pain improvement after one month (p=0.002). 
Painful muscle spasms recurred in 11 pts 3.5 months after injection. 










N = 52 
25 in AD film group, 












Significantly higher complete pain relief at rest and while eating in the AD film group versus topical anaesthetics 
group (82% vs 44% and 68% vs 22% respectively) 
No significant difference between AD film group vs topical anaesthetics group in duration of complete pain relief 
(30’ vs 30’-2h). 
Partial and complete pain relief was comparable in both groups. 
In the AD film group, median duration of grade 3-4 oral pain was 10 days versus 15 days in the topical 
anaesthetics group.  
 




Appendix D: Reported adverse events and toxicity 
Author Drug Comparison Number of patients Adverse event 
or toxicity 
Frequency Description 
Jiang et. al. 
2018 
Pregabalin Placebo N = 128 
64 in pregabalin 
group, 64 in placebo 
group 
SAE or AE 35 pts (54.7%) in the pregabalin group and 29 pts 
(45.3%) in the placebo group experienced at least one 
AE (p=0.29). 
 Dizziness: 12 in pregabalin group, 4 in placebo 
group 
 Somnolence: 13 in pregabalin group, 3 in placebo 
group 
 Facial oedema: one patient in pregabalin group 
discontinued the trial 
 Increased pain: two pts in the placebo group 
discontinued the trial 
Bar Ad et. al. 
2010 
Gabapentin No comparison N = 30 
29 included in 
analyses 
Toxicity 4 pts (13%) experienced mild side effects  Dizziness 
 Nausea 
 Vomiting 
 Follicular skin rash: one patient 
Bar Ad et. al. 
2010 
Gabapentin No comparison N = 42 Gabapentin 
related toxicity 
2 pts (5%) experienced mild side effects  Dizziness 
Kataoka et. 
al. 2016 
Gabapentin Standard pain control 
(acetominophen + 
N = 22 
20 included in 
Adverse events 
specific to 
3 pts with gabapentin related toxicities   Somnolence: two pts in gabapentin group 









Gabapentin Standard treatment 
(including narcotic 
pain medication) 
N = 46 NR 3 pts with gabapentin related toxicities  Vertigo and headaches: one patient 






(prepared in similar 
manner: Ora-Sweet SF 
= alcohol-free 
flavoured sugar-erfree 
syrup vehicle = placebo 
base solution 
N = 155 
140 included in 
primary endpoint 
analyses, 129 
included in crossover 
analyses 
Oral rinse side 
effects 
NR  Stinging and burning (numeric scale): mean of 
9.6 vs 4.0 (p<0.001), maximal at 5 minutes 
 Taste (numeric scale): mean AUC of 7.7 vs 5.1 
(p<0.018) 
 Drowsiness: AUC of -.2.4 in placebo vs -0.7 in 
doxepin rinse (p=0.0297) 
Ehrnrooth et. 
al. 2001 
Nortriptyline oral morphine 
(morphine chloride: 
start with 5mg x6, and 
additional doses of 5 
mg each; titration to 
acquire pain relief 
without intolerable 
side effects; steady 
state pts converted to 
morphine sulphate 
N = 43  
39 included in 
analyses 
19 in nortriptyline 
group, 20 in 
morphine group 
Side effects 14 pts experienced minor side effects in both groups  Nausea: 11 pts in nortriptyline group vs 8 in 
opioid group 
 Vomiting: 4 pts in nortriptyline group vs 1 
patient in opioid group 
 Constipation: 5 pts in nortriptyline group vs 8 pts 
in opioid group 
 Cardial arrhythmia: 1 patient in nortripyline 
group vs none in opioid group 
 Neurocortical: 4 pts in nortriptyline group vs 3 
pts in opioid group 




No comparison N = 19  Toxicity 7 pts   Painful injections 










N = 52 
25 in AD film group, 




No toxicity  No acute or chronic adverse effects on the oral 
mucosa or gastrointestinal tracts  
 No allergic dermal reactions 
 No cases of haematological toxicity 




Appendix E: Other reported outcomes 
Author Drug Comparison Number of patients Outcome Results 
Jiang et. al. 
2018 
Pregabalin Placebo N = 128 
64 in pregabalin 









Significant improvements in all subscales of POMS-SF, but not in Vigor-Activity and Confusion-
Bewilderment subscales in pregabalin vs placebo. 
 
Significant improvements in physiology and psychology domains of WHOQOL-BREF scores in pregabalin 
vs placebo (p=0.004 and p=0.01 resp.). 
 












CGIC scale showed 36 pts (57.1%) with treatment success in pregabalin group vs 10 pts (16.1%) in 
placebo group (p<0.001). 
 
12.5% of pts took rescue medication in the pregabalin group vs 40.6% in the placebo group (p<0.001). 
 
Compliance was comparable in both groups: 80.5% of pts took 80% or more of their prescribed 
medication. 
Bar Ad et. al. 
2010 
Gabapentin No comparison N = 30 











All pts developed mucositis. 
During the first 2 weeks of treatment, grade 1 and 2 mucositis occurred in 80% of the pts. 
By week 2, 3 and 4, grade 2 mucositis occurred in 13%, 53% and 73%  of the pts respectively. 
By week 5 and 6, grade 2 or 3 occurred in 80% of the pts.  
Grade 3 mucositis occurred in 6% of the pts. 
No grade 4 mucositis was reported. 
 
During week one of treatment, one patient (3%) reported dysphagia. 
By week 4 and 6, 53% of the pts and 60% reported grade 1 dysphagia respectively. 
Grade 2 dysphagia was reported by one patient (3%) during this trial, starting at week 3. 
Grade 3 dysphagia was reported by two pts (6%) during week 3 and by one patient (3%) by week 6. 
33% of pts did not report any swallowing difficulty. 
No grade 4 dysphagia was reported. 
Bart Ad et. al. 
2010 










All pts developed mucositis. 
Grade 1 and 2 mucositis occurred in 88% of the pts during the first 2 weeks of treatment. 
Grade 2 mucositis occurred in 44% of the pts during week 2. 
Grade 3 mucositis was not reported by week 2, but occurred in 17%, 45%, 60% and 81% of the pts by 
week 3, 4, 5 and 6 respectively. 
Grade 2 mucositis or higher occurred in 71%, 86%, 95% and 100% of the pts by week 3, 5, 5 and 6. 
No grade 4 mucositis was reported. 
 
During week one of treatment, 2 pts (5%) reported grade 1 dysphagia. 
By week 2 and 3, grade 1 or 2 dysphagia was reported by 38% and 52% of the pts respectively. 
By week 4, 76% of the pts reported dysphagia with 36% grade 2 or 3. 
By week 5 and 6, 95% of the pts reported dysphagia with 48% grade 2 or 3. 
No grade 4 dysphagia was reported. 
Kataoka et. 
al. 2016 
Gabapentin Standard pain control 
(acetominophen + 
opioids) 
N = 22 
20 included in 
analyses 
11 in SPC group, 9 in 
gabapentin group 




No significant decrease was observed in most QOL domains over 4 weeks radiotherapy between both 
groups. 
Weight gain was significantly higher in in the gabapentin group vs SPC group (p=0.0062). 
 
All pts experienced oral mucositis: grade 3 or 4 mucositis occurred in 45.5% of the pts in SPC group vs 
63.6% in gabapentin group. 
Starmer et. 
al. 2014 
Gabapentin Standard treatment 
(including narcotic 
pain medication) 








Later PEG use in gabapentin group vs control group (3.7 vs 2.29 weeks; p=0.013), earlier PEG removal in 
gabapentin vs control group (7.29 vs 32.56 weeks; 0.039). 
21.7% of pts in the gabapentin group never used their PEG tube vs 4.3% in the control group (p=0.038). 
Pts in the gabapentin group lost on average 7.45% weight vs 11% weight loss in the control group 
(p=0.037).  
 
Velopharyngeal closure, tongue base retraction, laryngeal elevation, epiglottic tilt, and pharyngeal 
constriction was less effected in the gabapentin group. 
26 
 
Significant lower PAS scores were found (1.89 vs 4; p=0.0052) in the gabapentin group, indicating better 
airway protection. 
Significant higher FOIS scores were found (5.4 vs 3.21; p=0.0003) in the gabapentin group, indicating more 






(prepared in similar 
manner: Ora-Sweet SF 
= alcohol-free flavored 
sugar-erfree syrup 
vehicle = placebo base 
solution 
N = 155 
140 included in 
primary endpoint 
analyses, 129 





Nortriptyline oral morphine 
(morphine chloride: 
start with 5mg x6, and 
additional doses of 5 
mg each; titration to 
acquire pain relief 
without introlerable 
side effects; steady 
state pts converted to 
morphine sulphate 
N = 43  
39 included in 
analyses 
19 in nortriptyline 
group, 20 in 
morphine group 
Depression Significant reduction in BDI scores in nortriptyline group vs oral morphine group (p=0.02).  




No comparison N = 19  Functionality and 
cramps 
Significant improvement in overall functional score (p=0.004) and muscular cramps (p=0.004). 
No significant improvement in jaw opening. 
 










N = 52 
25 in AD film group, 












Tumour control and 
survival 
Mucositis was observed in 88% of the pts in the AD film group vs 92% in the comparison group.  
 
 
17 pts in the AD film group did not require IV infusions or hyperalimentation vs 9 in the comparison group. 
Less weight loss and better weight recovery were observed in the AD film group vs the comparison group 
(not significant).  
 
No secondary bacterial or fungal infection of the oral cavity and/or oropharynx was observed in the AD 
film group vs 4 cases of oral infection and 2 cases of aspiration pneumonia in the comparison group. 
 
No significant difference in 3-year local control rate was found between both groups (96% vs 92%) and no 






Appendix F: Quality assessment 
Jiang et. al. 2017   
Domain Judgement Support for judgement  
Selection bias    
Random sequence 
generation 
LOW RISK Quote: "This trial was a randomized, double blind, placebo-controlled multicenter trial..." 
   Comment: Probably done 
Allocation concealment LOW RISK Quote: "The 1:1 random allocation, stratified by age (≤ 60 years or > 60 years) and participating center, 
was centralized using a computer-generated pseudorandom code with block size of four or six." 
   Comment: Probably done 
     
Performance bias    
Blinding of participants and 
personnel 
LOW RISK Quote: "Non-transparent envelopes with the allotted sequences inside were prepared and kept sealed 
to avoid revealing the sequences during the trial." "To ensure the double-blind principle, randomization 
was performed by an independent investigator who did not participate in enrolment. Assessors and 
patients were blinded to group allocation."  
   Comment: Probably done 
     
Detection bias    
Blinding of outcome 
assessment 
LOW RISK Quote: "To ensure the double-blind principle, randomization was performed by an independent 
investigator who did not participate in enrolment" 
   Comment: Probably done 
     
Attrition bias    
Incomplete outcome data LOW RISK 4/68 patients in the pregabalin group did not receive pregabalin due to pregnancy (n=1) or missed 
baseline data (n=3). 5/69 patients in the placebo group did not receive placebo because of migration to 
another city (n=2) or because of refusal to participate (n=3). 7/64 in the pregabalin group discontinued 
treatment because of adverse events, protocol violation, withdrawal of consent, lost to follow up or 
unable to contact. 8/64 in the placebo group discontinued treatment because of adverse events, 
protocol violation, withdrawal of consent, lost to follow-up or unable to contact.  
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Reporting bias    
Selective reporting LOW RISK All aspects described in the method section are reported as outcome 
     
Other bias    
Other souces of bias LOW RISK No other sources of bias detected 
 
 
Bar Ad et. al. 2010   
Domain Judgement Support for judgement  
Selection bias    
Random sequence 
generation 
HIGH RISK Non-randomised trial 
Allocation concealment HIGH RISK Non-randomised trial 
     
Performance bias    
Blinding of participants and 
personnel 
HIGH RISK All patients received gabapentin, there was no blinding 
     
Detection bias    
Blinding of outcome 
assessment 
HIGH RISK Retrospective trial, all patients received gabapentin, there was no control group 
     
Attrition bias    
Incomplete outcome data LOW RISK No incomplete outcome data, 30 cases were included and analysed in this retrospective trial 
     
Reporting bias    
Selective reporting LOW RISK All aspects described in the method section are reported as outcome 
     
Other bias    
29 
 
Other sources of bias HIGH RISK No power calculation and low sample size 
 
Bar Ad et. al. 2010   
Domain Judgement Support for judgement  
Selection bias    
Random sequence generation HIGH RISK Non-randomised trial 
Allocation concealment HIGH RISK Non-randomised trial 
     
Performance bias    
Blinding of participants and 
personnel 
HIGH RISK All patients received gabapentin, there was no blinding 
     
Detection bias    
Blinding of outcome 
assessment 
HIGH RISK Retrospective trial, all patients received gabapentin, there was no control group 
     
Attrition bias    
Incomplete outcome data LOW RISK No incomplete outcome data, 42 cases were included and analysed in this retrospective trial 
     
Reporting bias    
Selective reporting LOW RISK All aspects described in the method section are reported as outcome 
     
Other bias    
Other sources of bias HIGH RISK No power calculation and low sample size 
 
 
Kataoka et al   
Domain Judgement Support for judgement  
Selection bias    
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Random sequence generation LOW RISK Quote: "Patients were randomly assigned…" 
   Comment: Probably done 
Allocation concealment LOW RISK Quote: "… at a 1:1 ratio. Computer-assisted randomization without stratification was used." 
   Comment: Probably done 
Performance bias    
Blinding of participants and 
personnel 
UNCLEAR No information concerning blinding can be found 
     
Detection bias    
Blinding of outcome 
assessment 
UNCLEAR No information on blinding of outcome assessors was reported 
     
Attrition bias    
Incomplete outcome data UNCLEAR 2 from the 11 patients  in the intervention group were excluded, one due to termination because of 
total laryngectomy and 1 because of insufficient VAS and QOL questionnaire 
     
Reporting bias    
Selective reporting LOW RISK All aspects described in the method section are reported as outcome 
     
Other bias    
Other souces of bias LOW RISK No other sources of bias detected 
 
 
Starmer et al 2014   
Domain Judgement Support for judgement  
Selection bias    
Random sequence 
generation 
HIGH RISK Non-randomised trial 
Allocation concealment HIGH RISK Non-randomised trial 
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Performance bias    
Blinding of participants and 
personnel 
HIGH RISK Non randomised trial, partially retrospective study 
     
Detection bias    
Blinding of outcome 
assessment 
HIGH RISK Non randomised trial, partially retrospective study 
     
Attrition bias    
Incomplete outcome data LOW RISK No incomplete outcome data, all patients were included and analysed in this trial 
     
Reporting bias    
Selective reporting LOW RISK All aspects described in the method section are reported as outcome 
     
Other bias    
Other souces of bias LOW RISK No other sources of bias detected 
 
Leenstra et. al. 2014   
Domain Judgement Support for judgement  
Selection bias    
Random sequence generation LOW RISK Quote: "Randomization was performed…" 
   Comment: Probably done 
Allocation concealment LOW RISK Quote: "Patients were assigned to eighter doxepin-placebo (arm 1) or placebo-doxepin (arm 2) in a 
1:1 ratio using the Pocock and Simon dynamic allocation procedure, which balances the marginal 
distributions of the stratification factors." 
   Comment: Probably done 
     
Performance bias    
Blinding of participants and 
personnel 
LOW RISK Quote: "… and then blinded study personnel administered the rinse…" 
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   Comment: Probably done 
     
Detection bias    
Blinding of outcome 
assessment 
LOW RISK Quote: "After completion of the questionnaires from the blinded second dose, patients were 
unblinded…" 
   Comment: Probably done 
     
Attrition bias    
Incomplete outcome data LOW RISK 14 patients withdrew before start of study; 1 patient was ineligible; 6 pts refused further treatment 
after primary endpoint analyses, 1 patient stopped because of adverse events and 4 pts stopped 
because of other reasons. However, missing outcome data is balanced in numbers across intervention 
groups 
     
Reporting bias    
Selective reporting LOW RISK All aspects described in the method section were reported as outcome 
     
Other bias    
Other sources of bias LOW RISK No other sources of bias detected 
 
Ehrnrooth et. al. 2009   
Domain Judgement Support for judgement  
Selection bias    
Random sequence generation LOW RISK Quote: "… in a randomized design.." 
   Comment: Probably done 
Allocation concealment UNCLEAR No information on allocation concealment was reported 
     
Performance bias    
Blinding of participants and 
personnel 
UNCLEAR No information concerning blinding was reported 
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Detection bias    
Blinding of outcome 
assessment 
UNCLEAR No information on blinding of outcome assessors was reported 
     
Attrition bias    
Incomplete outcome data LOW RISK 2/20 patients in opioid group and 2/21 in TCA group non evaluable. One patient from the TCA group 
refused further participation because of dryness of the mouth, one patient in TCA group and 2 
patients in opioid group did not complete the questionnaires 
     
Reporting bias    
Selective reporting LOW RISK All aspects described in the method section are reported as outcome 
     
Other bias    
Other sources of bias LOW RISK No other sources of bias detected 
 
Hartl et. al. 2007   
Domain Judgement Support for judgement  
Selection bias    
Random sequence generation HIGH RISK Non-randomised trial 
Allocation concealment HIGH RISK Non-randomised trial 
     
Performance bias    
Blinding of participants and 
personnel 
HIGH RISK No comparison group 
     
Detection bias    
Blinding of outcome 
assessment 
HIGH RISK No comparison group 
     
Attrition bias    
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Incomplete outcome data LOW RISK No incomplete outcome data; all 19 included patients were analysed in this study 
     
Reporting bias    
Selective reporting LOW RISK All aspects described in the method section are reported as outcome 
     
Other bias    
Other sources of bias HIGH RISK No power calculation and low sample size 
 
Oguchi et. al. 1998   
Domain Judgement Support for judgement  
Selection bias    
Random sequence generation HIGH RISK Non randomised trial 
Allocation concealment HIGH RISK Non randomised trial 
     
Performance bias    
Blinding of participants and 
personnel 
HIGH RISK Non randomised trial, partially retrospective study 
     
Detection bias    
Blinding of outcome 
assessment 
HIGH RISK Non randomised trial, partially retrospective study 
     
Attrition bias    
Incomplete outcome data LOW RISK No incomplete outcome data, all patients were included and analysed in this trial 
     
Reporting bias    
Selective reporting HIGH RISK Not defined in advance what outcome would be reported  
     
Other bias    
Other sources of bias HIGH RISK No power calculation and low sample size 
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